ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 117 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,622,239 | -13.9% | 80,870 | +21.1% | 0.00% | 0.0% |
| Q2 2023 | $1,884,428 | +169210.7% | 66,800 | +3.2% | 0.00% | +100.0% |
| Q1 2023 | $1,113 | -4.7% | 64,707 | +11.6% | 0.00% | -50.0% |
| Q4 2022 | $1,168 | -99.9% | 57,977 | +5.7% | 0.00% | 0.0% |
| Q3 2022 | $1,188,000 | -7.5% | 54,857 | +20.1% | 0.00% | 0.0% |
| Q2 2022 | $1,284,000 | -26.6% | 45,684 | +20.5% | 0.00% | 0.0% |
| Q1 2022 | $1,750,000 | -41.3% | 37,923 | +7.0% | 0.00% | -50.0% |
| Q4 2021 | $2,980,000 | +29.0% | 35,448 | +2.3% | 0.00% | +33.3% |
| Q3 2021 | $2,310,000 | +36.1% | 34,666 | +8.7% | 0.00% | +50.0% |
| Q2 2021 | $1,697,000 | +27.8% | 31,890 | +4.2% | 0.00% | 0.0% |
| Q1 2021 | $1,328,000 | -21.2% | 30,609 | -5.7% | 0.00% | 0.0% |
| Q4 2020 | $1,686,000 | +325.8% | 32,457 | +168.0% | 0.00% | +100.0% |
| Q3 2020 | $396,000 | -37.2% | 12,110 | -7.8% | 0.00% | 0.0% |
| Q2 2020 | $631,000 | – | 13,141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |